Live Feeds
● TRACKER Updated 11d ago · 5 sources tracked

Summit Packs A Punch For Merck's Keytruda

Summit Therapeutics and Akeso report that ivonescimab extended lives more effectively than Merck's Keytruda in a Phase 3 head-to-head trial conducted in China. The drug cleared the overall survival bar, positioning it as a direct competitor to the established immunotherapy. While Summit claims the drug is beating Merck, some analysts remain skeptical of the results. This development marks a second time ivonescimab has bested Keytruda in trials within China, challenging the market dominance of Merck's flagship cancer treatment.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (5)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Ivonescimab outperformed Merck's Keytruda in a Phase 3 trial in China.
  • ✓ Summit Therapeutics and Akeso developed ivonescimab.
  • ✓ Ivonescimab cleared the overall survival bar in the Phase 3 lung cancer trial.
🛡️ Source Corroboration: 5 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Summit and Akeso announced that ivonescimab cleared the overall survival bar in a Phase 3 lung cancer trial against Keytruda.

Live updates

  1. Ivonescimab Outperforms Keytruda in Phase 3 Lung Cancer Trial

    Summit Therapeutics and Akeso report that ivonescimab extended lives more effectively than Merck's Keytruda in a Phase 3 head-to-head trial conducted in China. The drug cleared the overall survival bar, positioning it as a direct competitor to the established immunotherapy. While Summit claims the drug is beating Merck, some analysts remain skeptical of the results. This development marks a second time ivonescimab has bested Keytruda in trials within China, challenging the market dominance of Merck's flagship cancer treatment.

    Why it matters

    Keytruda is a primary standard of care for lung cancer globally. Ivonescimab is a bispecific antibody developed through a partnership between Summit and Akeso. Success in these trials could shift the treatment paradigm for patients in China and potentially other markets.

    What is confirmed

    • Ivonescimab outperformed Merck's Keytruda in a Phase 3 trial in China.
    • Summit Therapeutics and Akeso developed ivonescimab.
    • Ivonescimab cleared the overall survival bar in the Phase 3 lung cancer trial.

    Still unconfirmed

    • Some investors and analysts are not convinced by the trial results.

    What to watch next

    • FDA or other regulatory filings for ivonescimab outside of China
    • Detailed breakdown of overall survival data from the Phase 3 trial
    • Merck's official response to the head-to-head trial results
    Sources used for this update (5)
    1. Investor's Business Daily — Summit Packs A Punch For Merck's Keytruda — But Not Everyone Is Sold
    2. Fierce Pharma — Akeso, Summit’s ivonescimab extends lives in Keytruda head-to-head trial. What now?
    3. BioSpace — Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
    4. Barron's — Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug
    5. Endpoints News — Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community